STIs are on the rise. Chlamydia (CT) and gonorrhea (NG) can have serious long-term consequences including pelvic inflammatory disease (PID), ectopic pregnancy and infertility.1 Accurate testing and treatment are critical to protecting sexual and reproductive health. The Aptima Combo 2® assay delivers reliable results from multiple specimen types, including self and clinician-collected vaginal swabs with the Aptima® Multitest Swab — the preferred specimen type of the CDC for CT and NG testing.

Universal Screening

CDC continues to recommend CT/NG screening for all sexually active women 15-24 years old but recognizes that young women may be hesitant to disclose sexual activity. Thus, CDC recommends that providers might consider an opt-out, or universal, screening approach for adolescent and young adult females

Universal Screening benefits the lab, healthcare systems, HCPs and patients:1,3-4

Labs are reinforced as trusted partners to HCPs for STI testing and information.

Healthcare systems will improve clinical outcomes and quality metrics.

HCPs will have fewer uncomfortable conversations, identify and treat more infections, and improve quality metrics.

Patients’ reproductive health/ fertility is preserved.